

Lenz Sales and Distributing Inc 4825 Waverly Rd NEW BERLIN IL 62670 US Performance Materials and Technologies 115 Tabor Road Morris Plains, NJ 07950 ATTN: SDS Coordinator

September 21, 2024

Dear Sir or Madam:

As a Responsible Care® company, Honeywell is focused on maintaining a high quality Product Stewardship program. To that end, our customers are sent Safety Data Sheets (SDSs) whenever:

- you purchase a product for the first time in a given calendar year,
- a SDS is significantly revised and/or updated
- the product contains a chemical(s) that is listed under Section 313 of the Emergency Planning and Community Right-To-Know Act of 1986.

10322628 Genetron® 245fa

**Customer PO Number** 

**Customer Material Number** 

ICETHRM919

Enclosed are the current SDSs for Honeywell International Inc. products purchased by your company. It is imperative that you read and understand these SDSs, and that copies be permanently maintained on file at your facility. In addition, if you redistribute the products, these SDSs must also be provided to downstream employers receiving the products. If you or your department is not responsible for these files, please forward this information accordingly.

Should you have questions, or require any additional information about these products, please refer to Section 1 of the SDS for contact information.

Sincerely,

Honeywell Product Stewardship Global Operations

This letter was generated by electronic data processing and therefore has no signature.

Enclosure(s)

# Honeywell

## Genetron® 245fa

10322628			
Version 2.13	Re	evision Date 09/22/2023	Print Date 09/20/2024
SECTION 1. IDENTIFICATION			
SECTION 1. IDENTIFICATION			
Product name	: Gen	etron® 245fa	
Number	: 0000	00009878	
Product Use Description	: Refr	igerant, Heat transfer fluid	
		.g	
Manufacturer or supplier's	: Hone	eywell International Inc.	
details	115	Tabor Road	
For more information call		is Plains, NJ 07950-2546 522-8001	
		73-455-6300(Monday-Friday, 9	:00am-5:00pm)
In case of emergency call	: Med	lical: 1-800-498-5701 or +1-303	3-389-1414
		nsportation (CHEMTREC): 1-8	00-424-9300 or
	+1-7 :	03-527-3887	
	: (24 ł	nours/day, 7 days/week)	
SECTION 2. HAZARDS IDENTIF			
Emergency Overview			
Form	: Liqu	uefied gas	
Color	: colo	ourless	
Odor	: wea	ak	
Classification of the substa	nce or n	nixture	
		ases under pressure, Liquefied g	nas
or mixture		nple Asphyxiant	yas
GHS Label elements, includ	ling proc	cautionary statements	
	my prec	autionaly statements	
		Page 1 / 15	

	-	Honeywell
netron® 245fa		
<b>322628</b> sion 2.13	Revision Date 09/22/2023	Print Date 09/20/20
Symbol(s)	:	
Signal word	: Warning	
Hazard statements	: Contains gas under pressure; May displace oxygen and caus	
Precautionary statements	: <b>Prevention:</b> Use personal protective equip	ment as required.
	<b>Storage:</b> Protect from sunlight. Store in	a well-ventilated place.
Hazards not otherwise classified	: May cause eye and skin irritati May cause cardiac arrhythmia	
• • • • •		
anticipated carcinogen by NT	present at levels greater than or equar P, IARC, or OSHA. <b>CORMATION ON INGREDIENTS</b>	al to 0.1% is identified as a know
No component of this product anticipated carcinogen by NT	P, IARC, or OSHA.	al to 0.1% is identified as a know
No component of this product anticipated carcinogen by NT CTION 3. COMPOSITION/INF	P, IARC, or OSHA.	al to 0.1% is identified as a know
No component of this product anticipated carcinogen by NT CTION 3. COMPOSITION/INF	P, IARC, or OSHA.	
No component of this product anticipated carcinogen by NT CTION 3. COMPOSITION/INF Formula Chemical nature	P, IARC, or OSHA.   ORMATION ON INGREDIENTS  CHF2CH2CF3  Substance  name CAS-N	o. Concentration
No component of this product anticipated carcinogen by NT CTION 3. COMPOSITION/INF Formula Chemical nature Chemical	P, IARC, or OSHA. CORMATION ON INGREDIENTS : CHF2CH2CF3 : Substance name CAS-N e 460-73	o. Concentration
No component of this product anticipated carcinogen by NT CTION 3. COMPOSITION/INF Formula Chemical nature 1,1,1,3,3-Pentafluoropropane	P, IARC, or OSHA. CORMATION ON INGREDIENTS : CHF2CH2CF3 : Substance name CAS-N e 460-73	o. Concentration -1 100.00 % hing, give artificial respiration. If
No component of this product anticipated carcinogen by NT CTION 3. COMPOSITION/INF Formula Chemical nature (Chemical nature 1,1,1,3,3-Pentafluoropropane) CTION 4. FIRST AID MEASU	P, IARC, or OSHA.	o. Concentration -1 100.00 % hing, give artificial respiration. If
No component of this product anticipated carcinogen by NT CTION 3. COMPOSITION/INF Formula Chemical nature (Chemical nature 1,1,1,3,3-Pentafluoropropane) CTION 4. FIRST AID MEASU	P, IARC, or OSHA.         FORMATION ON INGREDIENTS         : CHF2CH2CF3         : Substance         name       CAS-N         e       460-73         RES         : Remove to fresh air. If not breatt breathing is difficult, give oxyger	o. Concentration -1 100.00 % hing, give artificial respiration.

# Honeywell

## Genetron® 245fa

10322628
----------

10322628			
Version 2.13		Revision Date 09/22/2023	Print Date 09/20/2024
		provided a qualified operator is preser	nt. Call a physician.
Skin contact	:	After contact with skin, wash immedia symptoms persist, call a physician. Ta clothing immediately. Wash contamina re-use.	ake off all contaminated
Eye contact	:	Rinse immediately with plenty of wate for at least 15 minutes. Call a physicia persists.	
Ingestion	:	If victim is fully conscious, give a cupfe vomiting without medical advice. Neve to an unconscious person. Call a phys	er give anything by mouth
Notes to physician			
Indication of immediate medical attention and special treatment needed, if necessary	:	Treat symptomatically.	
SECTION 5. FIREFIGHTING MEA	sı	IRES	
Suitable extinguishing media		The product is not flammable. Use extinguishing measures that are circumstances and the surrounding e Water spray Carbon dioxide (CO2) Dry chemical Foam	
Specific hazards during firefighting		<ul> <li>This product is not flammable at amb atmospheric pressure.</li> <li>However, this material can ignite whe pressure and exposed to strong igniti Container may rupture on heating.</li> <li>Cool closed containers exposed to fir Do not allow run-off from fire fighting courses.</li> <li>Vapours are heavier than air and can reducing oxygen available for breathin Exposure to decomposition products health.</li> </ul>	en mixed with air under ion sources. re with water spray. to enter drains or water n cause suffocation by ing.
		Page 3 / 15	

# Honeywell

## Genetron® 245fa

<b>322628</b> sion 2.13	Revision Date 09/22/2023	Print Data 00/20/2
5011 2.13		Print Date 09/20/2
	Fire may cause evolution o Hydrogen fluoride Gaseous hydrogen chloride Carbon oxides Halogenated compounds Carbonyl halides	
Special protective equipment for firefighters		explosion do not breathe fumes. Ning apparatus and protective suit. Kin areas.
TION 6. ACCIDENTAL RELI	ASE MEASURES	
Personal precautions, protective equipment and emergency procedures	must be kept away. Remove all sources of igniti Ventilate the area. Vapours are heavier than ai reducing oxygen available for Avoid accumulation of vapo	l upwind of spill/leak. quipment. Unprotected persons on. r and can cause suffocation by or breathing. urs in low areas. uld not return until air has been
Environmental precautions	Prevent further leakage or s	ter or sanitary sewer system. pillage if safe to do so. ide area (e.g. by containment or oil
Methods and materials for containment and cleaning up		nd, earth, diatomaceous earth, ntainer for disposal according to
TION 7. HANDLING AND ST	ORAGE	
Handling		
Precautions for safe	: Handle with care.	
	Page 4 / 15	

# Honeywell

## Genetron® 245fa

10322628			
Version 2.13		Revision Date 09/22/2023	Print Date 09/20/2024
handling		Do not use in areas without adequat Do not breathe vapours or spray mis Avoid contact with skin, eyes and cle Follow all standard safety precaution compressed gas cylinders. Use authorized cylinders only. Protect cylinders from physical dam Do not puncture or drop cylinders, ex excessive heat. Do not pierce or burn, even after use flame or any incandescent material. Do not remove screw cap until imme Always replace cap after use.	st. othing. ns for handling and use of age. kpose them to open flame or e. Do not spray on a naked
Advice on protection against fire and explosion	:	Can form a combustible mixture with atmospheric pressure. Keep product and empty container a of ignition.	
Storage			
Conditions for safe storage, including any incompatibilities	:	Pressurized container. Protect from to temperatures exceeding 55 °C. Keep containers tightly closed in a d place. Storage rooms must be properly ver Ensure adequate ventilation, especi Protect cylinders from physical dama Store away from incompatible subst	try, cool and well-ventilated ntilated. ally in confined areas. age.
SECTION 8. EXPOSURE CONTROL	OL	S/PERSONAL PROTECTION	
Protective measures	:	Ensure that eyewash stations and so the workstation location. Do not breathe vapours or spray mis Avoid contact with skin, eyes and cle	st.
Engineering measures	:	Use with local exhaust ventilation. Perform filling operations only at sta ventilation facilities.	tions with exhaust
Eye protection	:	Wear as appropriate:	
		Page 5 / 15	

# Honeywell

## Genetron® 245fa

## 10322628

sion 2.13	Revision Date 09/22/2023	Print Date 09/20/2
	Safety glasses with side-shields Safety goggles	
Hand protection	: Impervious gloves Gloves must be inspected prior to Replace when worn.	o use.
Skin and body protection	: Wear as appropriate: Solvent-resistant gloves Solvent-resistant apron and boots If splashes are likely to occur, we Protective suit	
Respiratory protection	<ul> <li>In case of insufficient ventilation vequipment.</li> <li>Wear a positive-pressure supplie</li> <li>For rescue and maintenance wor self-contained breathing apparate</li> <li>Use NIOSH approved respiratory</li> </ul>	d-air respirator. k in storage tanks use us.
Hygiene measures	<ul> <li>Handle in accordance with good in practice.</li> <li>Avoid contact with skin, eyes and Do not breathe vapours or spray Ensure adequate ventilation, esp Remove and wash contaminated Contaminated work clothing shou workplace.</li> <li>Keep working clothes separately. Wash hands before breaks and in product.</li> </ul>	d clothing. mist. ecially in confined areas. clothing before re-use. uld not be allowed out of the

Components	CAS-No.	Value	Control	Upda	Basis
			parameters	te	
1,1,1,3,3-Pentaflu oropropane	460-73-1	TWA : Time weighted average	1,644 mg/m3 (300 ppm)	2020	WEEL:US. OARS. WEELs Workplace Environmental Exposure Level Guide, as amended

Page 6 / 15

## Honeywell

#### Genetron® 245fa

10322628 Version 2.13 Print Date 09/20/2024 Revision Date 09/22/2023 **SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES** Physical state : Liquefied gas Color : colourless Odor : weak pН : Note: neutral Melting point/range : -103 °C Boiling point/boiling range : 15.3 °C Flash point : Note: Not applicable Evaporation rate : <1 Method: Compared to Ether (anhydrous). : > 1 Method: Compared to CCl4.

Lower flammability limit	: Note: None
Upper flammability limit	: Note: None
Vapor pressure	: 1,227 hPa at 20 °C(68 °F) 3,882 hPa

Vapor density : 4.6 Note: (Air = 1.0)

Density

Page 7 / 15

at 54.4 °C(129.9 °F)

: 1.32 g/cm3 at 20 °C

# Honeywell

## Genetron® 245fa

sion 2.13	Revision Date 09/22/2023	Print Date 09/20/20
Water solubility	: 7.18 g/l	
Solubility in other solvents	: Medium: Methanol Note: partly soluble Medium: Diethylether	
	Note: partly soluble	
Partition coefficient: n-octanol/water	: log Pow: 1.35 at 21.5 °C Note: The product is more soluble	in octanol.
Ignition temperature	: 412 °C	
Decomposition temperature	: >250 °C	
Molecular weight	: 134.03 g/mol	
CTION 10. STABILITY AND R	EACTIVITY	
CTION 10. STABILITY AND R Reactivity	EACTIVITY : Not classified as a reactivity hazar	d.
Reactivity	: Not classified as a reactivity hazar	ge conditions. n sunlight and do not expose ith air at pressures above
Reactivity Chemical stability	<ul> <li>Not classified as a reactivity hazard</li> <li>Stable under recommended storag</li> <li>Pressurized container. Protect from to temperatures exceeding 55 °C. Can form a combustible mixture w atmospheric pressure.</li> </ul>	ge conditions. n sunlight and do not expose ith air at pressures above
Reactivity Chemical stability Conditions to avoid	<ul> <li>Not classified as a reactivity hazard</li> <li>Stable under recommended storag</li> <li>Pressurized container. Protect from to temperatures exceeding 55 °C. Can form a combustible mixture w atmospheric pressure. Do not mix with oxygen or air abov</li> <li>Strong oxidizing agents Finely divided magnesium</li> </ul>	ge conditions. n sunlight and do not expose ith air at pressures above

Revision Date 09/22/2023 Print Date 09/20/202
Carbonyl halides Gaseous hydrogen chloride (HCI).
FORMATION
: LC50: > 200000 ppm Exposure time: 4 h Species: Rat Note: No deaths Evidence of transient anesthetic effect.
: LC50: > 100000 ppm Exposure time: 4 h Species: Mouse Note: No deaths Evidence of transient underactivity during exposure.
: LD50: > 2,000 mg/kg Species: Rabbit
<ul> <li>Cardiac sensitization Species: dogs Note: No effects noted at 35,000 ppm, the threshold for induction of cardiac arrhythmias in the presence of injected adrenalin was 44,000 ppm.</li> </ul>
: Species: Rat NOEL: 50000 ppm Note: Embryotoxicity Not a teratogen
: Species: rat (pups) NOEL: 50000 ppm
: Species: rat (dams) NOEL: 2000 ppm Note: due to decrease in body weight gains at 10,000 ppm and 50,000 ppm
Page 9 / 15

# Honeywell

## Genetron® 245fa

Version 2.13       Revision Date 09/22/2023       Print Date 09/20/20         :       Species: Rat Method: 2 Generation Inhalation Toxicity Note: Exposures 6hrs/day, 7 days/wk at 0(control), 2000, 10,000 and 50,000 ppm.         :       Species: rat (dams) Note: Toxicity seen in dams at 10,000 and 50,000 ppm and in pups at 50,000 ppm. Increased mortality late in the lactation phase of the study.         :       Species: Rat Note: 28-day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels: 0,500, 2000, 10,000 and 50,000 ppm         :       Species: Rat Note: 29-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm         :       Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm         :       Note: Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm. This was not noted at the 500 or 2,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study	<ul> <li>Species: Rat Method: 2 Generation Inhalation Toxicity Note: Exposures 6hrs/day, 7 days/wk at 0(control), 2000, 10,000 and 50,000 ppm.</li> <li>Species: rat (dams) Note: Toxicity seen in dams at 10,000 and 50,000 ppm and in pups at 50,000 ppm. Increased mortality late in the lactation phase of the study.</li> <li>Species: Rat Note: 28-day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels: 0,500, 2000, 10,000 and 50,000 ppm</li> <li>Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm</li> <li>Species: Rat Note: 0-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm</li> <li>Note: Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-2451 is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm.</li> <li>Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.</li> <li>Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negative</li> <li>Species: Mouse Cell type: Bone marrow</li> </ul>	0322628		
Method: 2 Generation Inhalation Toxicity         Note: Exposures 6hrs/day, 7 days/wk at 0(control), 2000, 10,000 and 50,000 ppm.         Species: rat (dams)         Note: Toxicity seen in dams at 10,000 and 50,000 ppm and in pups at 50,000 ppm. Increased mortality late in the lactation phase of the study.         : Species: Rat         Note: 28-day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels: 0,500, 2000, 10,000 and 50,000 ppm         : Species: Rat         Note: 30-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm         : Species: Rat         Note: 0-verall, subchronic studies showed dose-related         increases in urinary fluoride levels, urine volumes and water         consumption. Increases were noted in hematological         parameters, BUN levels and serum liver enzyme activities         (GOT, GPT). These increases did not follow a dose response;         however, they indicate that HFC-245fa is metabolized in the         liver . Significant recovery was noted in these parameters         following a 2-week, non-exposure period which followed the         28-day exposure period. No histopathological effects were         noted in the 28-day study. The 90-day study noted an increase         in incidence and severity (trace to moderate) of mycarditis         (inflammation of the heart muscle) at 10,000 and 50,000 ppm.	Method: 2 Generation Inhalation Toxicity Note: Exposures 6hrs/day, 7 days/wk at 0(control), 2000, 10,000 and 50,000 ppm.         Species: rat (dams) Note: Toxicity seen in dams at 10,000 and 50,000 ppm and in pups at 50,000 ppm. Increased mortality late in the lactation phase of the study.         Species: Rat Note: 28-day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels: 0,500, 2000, 10,000 and 50,000 ppm         Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm         Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm         Species: Rat Note: 00-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm         Species: Rat Note: 0-day Inhalation Study Dose levels: urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period Which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm.         Genotoxicity in vitro       Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.         <	ersion 2.13	Revision Date 09/22/2023	Print Date 09/20/2024
Note: Toxicity seen in dams at 10,000 and 50,000 ppm and in pups at 50,000 ppm. Increased mortality late in the lactation phase of the study.: Species: Rat Note: 28-day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels: 0,500, 2000, 10,000 and 50,000 ppm: Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm: Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm: Note: Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm.Genotoxicity in vitro: Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.: Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negativeGenotoxicity in vivo: Species: Mouse Cell type: Bone marrow	Note: Toxicity seen in dams at 10,000 and 50,000 ppm and in pups at 50,000 ppm. Increased mortality late in the lactation phase of the study.:Species: Rat Note: 24 day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels: 0,500, 2000, 10,000 and 50,000 ppm:Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm:Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm:Note: Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm.:Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.:Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negative:Species: Mouse Cell type: Bone marrow Application Route: Inhalation		Method: 2 Generation Inhalation To Note: Exposures 6hrs/day, 7 days/v 10,000 and 50,000 ppm.	
Note: 28-day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels: 0,500, 2000, 10,000 and 50,000 ppm:Species: Rat Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm:Note: Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 amd 50,000 ppm. This was not noted at the fool or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm.Genotoxicity in vitro:Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.Genotoxicity in vitro:Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negativeGenotoxicity in vitro:Species: Mouse Cell type: Bone marrow	Note:28-day Inhalation Study NOAEL (No observed adverse effect level) - 50,000 ppm NOEL - 500 ppm Dose levels:0,500, 2000, 10,000 and 50,000 ppm:Species: Rat Note:90-day Inhalation Study Dose levels:0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm:Note:Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycaritis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm.Genotoxicity in vitro:Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.Genotoxicity in vitro:Species: Mouse Cell type: Bone marrow Application Route: Inhalation		Note: Toxicity seen in dams at 10,0 pups at 50,000 ppm. Increased mo	
Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm: Note: Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm.Genotoxicity in vitro: Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.:Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negativeGenotoxicity in vivo:Species: Mouse Cell type: Bone marrow	Note: 90-day Inhalation Study Dose levels: 0,500, 2000, 10,000 and 50,000 ppm NOAEL (No observed adverse effect level) - 2,000 ppm: Note: Overall, subchronic studies showed dose-related increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm.Genotoxicity in vitro: Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.Genotoxicity in vivo: Species: Mouse Cell type: Bone marrow Application Route: Inhalation		Note: 28-day Inhalation Study NOA effect level) - 50,000 ppm NOEL - 5	
increases in urinary fluoride levels, urine volumes and water consumption. Increases were noted in hematological parameters, BUN levels and serum liver enzyme activities (GOT, GPT). These increases did not follow a dose response; however, they indicate that HFC-245fa is metabolized in the liver. Significant recovery was noted in these parameters following a 2-week, non-exposure period which followed the 28-day exposure period. No histopathological effects were noted in the 28-day study. The 90-day study noted an increase in incidence and severity (trace to moderate) of mycarditis (inflammation of the heart muscle) at 10,000 and 50,000 ppm. This was not noted at the 500 or 2,000 ppm dose levels nor was it seen the 28-day study at 50,000 ppm.Genotoxicity in vitro:Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.Genotoxicity in vivo:Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negativeGenotoxicity in vivo:Species: Mouse Cell type: Bone marrow	Genotoxicity in vivo: Cell type: Human lymphocytes Result: Weak positive activation without S9 at 30% v/v; not active time set with S9 up to 70% v/v.Genotoxicity in vivo: Species: Mouse Cell type: Bone marrow Application Route: Inhalation		Note: 90-day Inhalation Study Dose 10,000 and 50,000 ppm NOAEL (N	
Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.         : Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negative         Genotoxicity in vivo       : Species: Mouse Cell type: Bone marrow	Result: Weak positive activation without S9 at 30% v/v; not active with S9 up to 70% v/v.         : Test Method: Ames test Metabolic activation: with and without metabolic activation Result: negative         Genotoxicity in vivo       : Species: Mouse Cell type: Bone marrow Application Route: Inhalation		increases in urinary fluoride levels, consumption. Increases were noted parameters, BUN levels and serum (GOT, GPT). These increases did r however, they indicate that HFC-24 liver. Significant recovery was note following a 2-week, non-exposure p 28-day exposure period. No histopa noted in the 28-day study. The 90-c in incidence and severity (trace to r (inflammation of the heart muscle) a This was not noted at the 500 or 2,0	urine volumes and water d in hematological liver enzyme activities not follow a dose response; d in these parameters beriod which followed the athological effects were day study noted an increase noderate) of mycarditis at 10,000 and 50,000 ppm. 00 ppm dose levels nor was
Metabolic activation: with and without metabolic activation       Result: negative         Genotoxicity in vivo       :       Species: Mouse         Cell type: Bone marrow       :	Genotoxicity in vivo       :       Species: Mouse Cell type: Bone marrow Application Route: Inhalation	Genotoxicity in vitro	Result: Weak positive activation with	thout S9 at 30% v/v; not
Cell type: Bone marrow	Cell type: Bone marrow Application Route: Inhalation		Metabolic activation: with and witho	out metabolic activation
	Page 10 / 15	Genotoxicity in vivo	Cell type: Bone marrow Application Route: Inhalation	
Page 10 / 15			Page 10 / 15	

SAFETY DATA SHEET	Honeywell
enetron® 245fa	
0322628	
Version 2.13	Revision Date 09/22/2023 Print Date 09/20/202
	Method: Mutagenicity (micronucleus test) Result: negative
ECTION 12. ECOLOGICAL INFOR	RMATION
Ecotoxicity effects	
Toxicity to fish	<ul> <li>EC50: &gt; 81.8 mg/l</li> <li>Exposure time: 96 h</li> <li>Species: Oncorhynchus mykiss (rainbow trout)</li> </ul>
	<ul> <li>NOEC: &gt; 10 mg/l Exposure time: 96 h Species: Oncorhynchus mykiss (rainbow trout)</li> </ul>
Toxicity to daphnia and other aquatic invertebrates	: EC50: > 97.9 mg/l Exposure time: 48 h Species: Daphnia magna (Water flea)
	: NOEC: > 97.9 mg/l Exposure time: 48 h Species: Daphnia magna (Water flea)
Toxicity to algae	: Growth inhibition EC50: > 118 mg/l Species: Algae Method: OECD Test Guideline 201
Elimination information (pers	istence and degradability)
Bioaccumulation	: Note: No data available
Mobility	: Note: No data available
Biodegradability	: Note: No data available
	Page 11 / 15

information Agency Cle This productor to global w with provis recovered. Refer to securace Disposal methods Observe all regulations Note Observe all regulations Note Where post SECTION 14. TRANSPORT INFORMATION DOT UN/ID No. : Proper shipping name Class Packing group Hazard Labels IATA UN/ID No. : Class Packing group Hazard Labels Class Hazard Labels Hazard Labels	
ersion 2.13       Revision I         Further information on ecology         Additional ecological information       This produte Agency Clean this produte to global weith provis recovered. Refer to sequence performed and the provise recovered. Refer to sequence performed and the provise recovered and the provise recover and the provise	
Tersion 2.13       Revision I         Further information on ecology         Additional ecological information       This produte Agency Clean this produte to global weith provis recovered. Refer to sequence ptal to global weith provis recovered. Refer to sequence ptal to global weith provise recovered. Refer to global weith prove ptal to global weith prove ptal to global weit	Nata 00/22/2022
Additional ecological information  This produce Agency Cle This produce to global w with provis recovered. Refer to see unacceptal EECTION 13. DISPOSAL CONSIDERATIONS Disposal methods  Observe al regulations Note  Where pose EECTION 14. TRANSPORT INFORMATION DOT UN/ID No. Proper shipping name Class Packing group Hazard Labels IATA UN/ID No. Class Packing group Hazard Labels Class Packing instruction (cargo :: aircraft) Packing instruction (cargo :: Attal (passenger aircraft)	Date 09/22/2023 Print Date 09/20/2024
information       Agency Clear This produto global wwith provis recovered. Refer to set unacceptal         ECTION 13. DISPOSAL CONSIDERATIONS         Disposal methods       : Observe al regulations         Note       : Where post         ECTION 14. TRANSPORT INFORMATION         DOT       UN/ID No.         Proper shipping name       :         Class         Packing group         Hazard Labels       :         Class       :         Packing instruction (cargo instruction (cargo instruction (cargo instruction (cargo instruction (cargo instruction (cargo instruction (passenger aircraft))	
Disposal methods       : Observe all regulations         Note       : Where possion         ECTION 14. TRANSPORT INFORMATION       :         DOT       UN/ID No.       :         Poper shipping name       :         Class       Packing group         Hazard Labels       :         Class       :         Packing instruction (cargo       :         Packing instruction (cargo       :         Packing instruction (cargo       :         Packing instruction       :	et is subject to U.S. Environmental Protection can Air Act Regulations at 40 CFR Part 82. et contains greenhouse gases which may contribute arming. Do NOT vent to the atmosphere. To comply ons of the U.S. Clean Air Act, any residual must be ctions 610 and 612 for list of acceptable and ole uses for this product.
Note       Where possible         ECTION 14. TRANSPORT INFORMATION       Image: Class         DOT       UN/ID No.       Image: Class         Proper shipping name       Image: Class         Packing group       Hazard Labels         IATA       UN/ID No.       Image: Class         IATA       Unit Unit Unit Unit Unit Unit Unit Unit	Federal, State, and Local Environmental
DOTUN/ID No. Proper shipping name:Class Packing group Hazard Labels:IATAUN/ID No. Description of the goods:Class Hazard Labels:Class Description of the goods:Class Packing instruction (cargo aircraft) Packing instruction (passenger aircraft):	sible recycling is preferred to disposal or incineration.
Description of the goods:Class:Hazard Labels:Packing instruction (cargo:aircraft)Packing instructionPassenger aircraft)	UN 3163 LIQUEFIED GAS, N.O.S. (1,1,1,3,3-Pentafluoropropane) 2.2 2.2
IMDG UN/ID No. :	UN 3163 LIQUEFIED GAS, N.O.S. (1,1,1,3,3-Pentafluoropropane) 2.2 2.2 200 200
	UN 3163 LIQUEFIED GAS, N.O.S. (1,1,1,3,3-PENTAFLUOROPROPANE) 2.2
Pag	e 12 / 15

# Honeywell

## Genetron® 245fa

<b>0322628</b> ersion 2.13	Revision Date 09/22/2023	Print Date 09/20/202		
Hazard Labels EmS Number Marine pollutant	: 2.2 : F-C, S-V : no			
SECTION 15. REGULATORY INFORMATION				
Inventories				
US. Toxic Substances Control Act	: On TSCA Inventory			
Australia. Inventory of Industrial Chemicals (AIIC), as amended	: On the inventory, or in compliance with the	e inventory		
Canada. Canadian Environmental Protection Act (CEPA). Domestic Substances List (DSL)	: All components of this product are on the 0	Canadian DSL		
Japan. Kashin-Hou Law List	: On the inventory, or in compliance with the	e inventory		
Korea. Existing Chemicals Inventory (KECI)	: On the inventory, or in compliance with the	e inventory		
Philippines. Inventory of Chemicals and Chemical Substances (PICCS)	: Not in compliance with the inventory			
China. Inventory of Existing Chemical Substances (IECSC)	: On the inventory, or in compliance with the	e inventory		
New Zealand. Inventory of Chemicals (NZIoC), as published by ERMA New Zealand	: On the inventory, or in compliance with the	e inventory		
Taiwan Chemical Substance Inventory (TCSI)	: On the inventory, or in compliance with the	e inventory		
National regulatory informa	tion			
	Page 13 / 15			

## Honeywell

#### Genetron® 245fa

#### 10322628

0322628			
ersion 2.13	Revision Date 09/22/2023	Print Date 09/20/2024	
SARA 302 Components	: No chemicals in this material are sub	viect to the reporting	
SARA 302 Components	requirements of SARA Title III, Section		
		511002.	
SARA 313 Components	: This material does not contain any cl		
	known CAS numbers that exceed the		
	reporting levels established by SARA	A The III, Section 313.	
SARA 311/312 Hazards	: Sudden Release of Pressure Hazard		
	Acute Health Hazard		
	•		
California Prop. 65	· · <b>^</b>		
	WARNING: This product can e		
	listed below, known to the State of California to cause cancer.		
	For more information go to www.P65	ovvarnings.ca.gov.	
	Dichloromethane	75-09-2	
Massachusetts RTK	: Dichloromethane	75-09-2	
		75 00 0	
Pennsylvania RTK	: Dichloromethane	75-09-2	
ECTION 16. OTHER INFORM	<b>IATION</b>		
	HMIS III NFPA		
Health hazard	: 2 2 · 1 1		
Flammability Physical Hazard	: 1 1 : 0		
Instability	: 0		
Hazard rating and rating s	ystems (e.g. HMIS® III, NFPA): This informa	tion is intended solely for the u	
of individuals trained in the			

#### Further information

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and

Page 14 / 15

## Honeywell

#### Genetron® 245fa

#### 10322628

Version 2.13

Revision Date 09/22/2023

Print Date 09/20/2024

may not be valid for such material used in combination with any other materials or in any process, unless specified in the text. Final determination of suitability of any material is the sole responsibility of the user. This information should not constitute a guarantee for any specific product properties.

Changes since the last version are highlighted in the margin. This version replaces all previous versions.

Previous Issue Date: 08/08/2018

Prepared by Honeywell Performance Materials and Technologies Product Stewardship Group

Page 15 / 15